8-K: Herbalife Q2 Adjusted EBITDA Beats, Full-Year Outlook Raised

Herbalife Ltd. reported second-quarter 2025 financial results, with adjusted EBITDA exceeding guidance and a subsequent raise in full-year net sales and adjusted EBITDA outlook.

Summary

• Net sales for Q2 2025 were $1.3 billion, a 1.7% decrease year-over-year, including 170 basis points of foreign currency headwinds, but flat on a constant currency basis.
• Net income attributable to Herbalife significantly increased to $49.3 million in Q2 2025 from $4.7 million in Q2 2024.
• Adjusted EBITDA reached $173.6 million, surpassing guidance, with adjusted EBITDA at constant currency of $189.6 million also exceeding expectations.
• Diluted EPS was $0.48, and adjusted diluted EPS was $0.59, which includes a $0.11 year-over-year foreign currency headwind.
• Gross profit margin improved to 78.0% in Q2 2025, up from 77.9% in Q2 2024, benefiting from pricing and lower inventory write-downs.
• The company redeemed $50.0 million of 7.875% Senior Notes due 2025 in June 2025, with $147.3 million remaining outstanding and due in September 2025.
• Full-year 2025 guidance for net sales and adjusted EBITDA has been raised, and capital expenditures guidance has been reduced.
• New product MultiBurn and the beta version of the Pro2col digital platform were launched in July 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to adjusted EBITDA exceeding guidance, a significant increase in net income, and a raised full-year outlook for both net sales and adjusted EBITDA. Strategic initiatives like new product launches and digital platform development also contribute positively. However, the slight decline in reported net sales and flat worldwide distributor growth temper the overall score.

Positives

• Adjusted EBITDA of $173.6 million exceeded guidance for Q2 2025.
• Adjusted EBITDA at constant currency of $189.6 million also exceeded guidance.
• Full-year 2025 guidance for net sales and adjusted EBITDA was raised, indicating improved future expectations.
• Capital expenditures guidance for full-year 2025 was reduced from $90-$120 million to $75-$95 million.
• Gross profit margin increased to 78.0% in Q2 2025, benefiting from pricing and lower inventory write-downs.
• Net income attributable to Herbalife significantly improved to $49.3 million in Q2 2025 from $4.7 million in Q2 2024.
• The company launched MultiBurn, a new weight-loss supplement, and unveiled the beta version of its Pro2col digital platform and a healthy lifespan supplement.
• Four out of five regions reported year-over-year growth in new distributors, with Latin America up 16%.
• The company remains on track to reduce outstanding debt to $1.4 billion by the end of 2028.
• The revolving credit facility was undrawn as of June 30, 2025.

Negatives

• Net sales decreased by 1.7% year-over-year in Q2 2025, impacted by 170 basis points of foreign currency headwinds.
• Adjusted EBITDA margin was down 30 basis points versus Q2 2024, primarily due to foreign currency headwinds.
• Diluted EPS and adjusted diluted EPS were negatively impacted by a $0.11 year-over-year foreign currency headwind.
• The number of distributors joining worldwide in Q2 2025 was flat year-over-year, reflecting a challenging comparison to the strong early momentum of the Herbalife Premier League program in Q2 2024.

Risks

• Potential impacts of current global economic conditions, including inflation, unfavorable foreign exchange rate fluctuations, and tariffs, on the company, its Members, customers, supply chain, and the world economy.
• Ability to attract and retain Members (distributors) and influence their actions.
• Noncompliance with, or improper action by employees or Members in violation of, applicable U.S. and foreign laws, rules, and regulations.
• Adverse publicity associated with the company or the direct-selling industry, including the ability to comfort the marketplace and regulators regarding compliance with applicable laws.
• Changing consumer preferences and demands and evolving industry standards, including with respect to climate change, sustainability, and other environmental, social, and governance matters.
• The competitive nature of the business and industry.
• Legal and regulatory matters, including regulatory actions concerning, or legal challenges to, products or network marketing program and product liability claims, and compliance with the FTC Consent Order.
• Risks associated with operating internationally and in China.
• Ability to execute growth and other strategic initiatives, including restructuring efforts and increased market penetration.
• The effectiveness and acceptance of new technology-driven initiatives, including the development and deployment of artificial intelligence.
• Material disruption to the business caused by natural disasters, catastrophic events, acts of war or terrorism (e.g., Ukraine, Middle East), cybersecurity incidents, pandemics, and/or other acts by third parties.
• Ability to adequately source ingredients, packaging materials, and other raw materials and manufacture and distribute products.
• Noncompliance with privacy laws, rules, or regulations or any security breach involving confidential information.
• Contractual limitations on the ability to expand or change the direct-selling business model.
• Sufficiency of trademarks and other intellectual property.
• Product concentration.
• Reliance upon, or the loss or departure of any member of, the senior management team.
• Ability to integrate and capitalize on acquisition transactions.
• Restrictions imposed by covenants in agreements governing indebtedness.
• Risks related to convertible notes.
• Changes in, and uncertainties relating to, the application of transfer pricing, income tax, customs duties, value added taxes, and other tax laws, treaties, and regulations, or their interpretation.
• Incorporation under the laws of the Cayman Islands.
• Share price volatility related to speculative trading and certain traders shorting common shares.

Future Outlook

The company has raised its full-year 2025 guidance for both net sales and adjusted EBITDA, reflecting increased confidence in future performance. Net sales are now projected to be between a 1.0% decline and a 3.0% increase year-over-year on a reported basis, and 0.0% to 4.0% on a constant currency basis. Adjusted EBITDA is expected to range from $640 million to $660 million on a reported basis, and $685 million to $705 million on a constant currency basis. Capital expenditures guidance for the full year has been reduced to $75 million to $95 million. For the third quarter of 2025, net sales are guided to be +0.5% to +4.5% year-over-year, and adjusted EBITDA is projected between $150 million and $160 million. The company also plans further expansion of its Diamond Development Mastermind Program to India in August 2025 and additional markets in 2026, and the commercial launch of its healthy lifespan supplement in Q4 2025.

Management Comments

• "Net sales were in line with our expectations, while adjusted EBITDA exceeded our expectations. We continue to execute with financial discipline and remain firmly on track to reduce our outstanding debt to $1.4 billion by the end of 2028." John DeSimone, Chief Financial Officer.
• "We delivered solid second-quarter results and raised our full-year net sales and adjusted EBITDA guidance. With the launch of MultiBurn, the beta unveiling of our AI-assisted Pro2col app and the early release of our first healthy lifespan supplement, we’re taking bold steps that reinforce our commitment to innovation, transformative growth and long-term value creation." Stephan Gratziani, CEO.

Industry Context

Herbalife operates within the global health and wellness industry, specifically in the direct-selling segment for nutrition and weight management products. The launch of MultiBurn, a non-pharmaceutical weight-loss solution, positions the company to address consumer demand for metabolic health support amidst the rise of pharmaceutical weight-loss solutions. The unveiling of the Pro2col digital platform and a healthy lifespan supplement indicates a strategic move towards integrating digital health solutions and expanding into the longevity market, aligning with broader industry trends of personalized wellness and technology adoption. The flat year-over-year distributor growth worldwide, despite regional successes, suggests ongoing challenges in the direct-selling model, potentially due to market saturation or evolving consumer purchasing habits, requiring continued investment in distributor engagement programs like the Flex45 Challenge and Premier League.

Comparison to Industry Standards

• Herbalife's adjusted EBITDA margin of 13.8% in Q2 2025, while down 30 basis points year-over-year, provides a benchmark for profitability within the direct selling and nutritional supplement industry. Comparable companies like Nu Skin Enterprises (NUS) and USANA Health Sciences (USNA) also operate with similar direct-selling models and face similar challenges with foreign exchange headwinds and distributor engagement.
• The company's total leverage ratio of 3.0x at June 30, 2025, indicates its debt level relative to its earnings. This metric is crucial for assessing financial health compared to industry peers, where leverage ratios can vary significantly based on business model and capital structure.
• The flat year-over-year growth in new distributors worldwide, despite strong regional performance in Latin America (up 16%), highlights the varying market dynamics within the direct selling industry. Companies like Amway or Mary Kay, while private, also rely heavily on distributor networks, and their ability to recruit and retain distributors is a key performance indicator for the sector.
• The strategic focus on new product development (MultiBurn, healthy lifespan supplement) and digital platforms (Pro2col app) aligns with broader industry trends seen in consumer health, where companies are increasingly leveraging science-backed ingredients and technology to enhance product offerings and customer engagement. This proactive approach is essential for maintaining competitiveness against both traditional and emerging wellness brands.

Legal Proceedings

• Legal and regulatory matters, including regulatory actions concerning, or legal challenges to, products or network marketing program and product liability claims, and compliance with the Consent Order entered into with the Federal Trade Commission (FTC).

Stakeholder Impact

• Shareholders: Positive impact from exceeding earnings guidance, raised full-year outlook, and efforts to reduce debt, potentially leading to increased share price confidence.
• Employees: Continued strategic initiatives and product development may indicate stability and growth opportunities.
• Customers: Benefit from new product offerings like MultiBurn and the Pro2col digital platform, enhancing health and wellness solutions.
• Distributors: Engagement programs like Flex45 Challenge and Premier League aim to support and grow the distributor network, though worldwide growth was flat in Q2.
• Creditors: Debt reduction efforts and an undrawn revolving credit facility indicate prudent financial management, potentially improving creditworthiness.

Next Steps

• Commercial launch of healthy lifespan supplement in the U.S. and Puerto Rico planned for the fourth quarter of 2025.
• Expansion of the Diamond Development Mastermind Program to India in August 2025, with additional markets to follow in 2026.
• Further expansion of the healthy lifespan supplement to additional markets beginning in 2026.
• Continued execution of financial discipline to reduce outstanding debt to $1.4 billion by the end of 2028.
• Gathering valuable feedback from distributors engaged in the Pro2col Beta1 release ahead of commercial launch.

Key Dates

Recommendation

While Herbalife exceeded adjusted EBITDA guidance and raised its full-year outlook, indicating operational strength and management's confidence, the reported net sales still experienced a slight decline year-over-year due to foreign currency headwinds. The flat worldwide distributor growth also presents a challenge, suggesting the core direct-selling model faces ongoing headwinds despite regional successes. The company is making strategic moves with new product launches and digital platforms, which are positive long-term drivers. However, the inherent risks of the direct-selling model, regulatory scrutiny, and currency fluctuations warrant a 'hold' recommendation. Investors should monitor the effectiveness of new initiatives in driving sustainable sales and distributor growth, as well as the progress on debt reduction, before considering a stronger position.

Keywords

Herbalife, HLF, Nutrition, Wellness, Direct Selling, Multi-level Marketing, Dietary Supplements, Weight Management, Financial Results, Earnings, SEC Filing, Q2 2025, EBITDA, Net Sales, EPS, Debt Reduction, Product Launch, Digital Platform